|
1
|
Cristóbal I, Garcia-Orti L, Cirauqui C,
Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ and Odero MD:
Overexpression of SET is a recurrent event associated with poor
outcome and contributes to protein phosphatase 2A inhibition in
acute myeloid leukemia. Haematologica. 97:543–550. 2012. View Article : Google Scholar :
|
|
2
|
von Lindern M, van Baal S, Wiegant J, Raap
A, Hagemeijer A and Grosveld G: Can, a putative oncogene associated
with myeloid leukemogenesis, may be activated by fusion of its 3′
half to different genes: Characterization of the set gene. Mol Cell
Biol. 12:3346–3355. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li M, Guo H and Damuni Z: Purification and
characterization of two potent heat-stable protein inhibitors of
protein phosphatase 2A from bovine kidney. Biochemistry.
34:1988–1996. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cervoni N, Detich N, Seo SB, Chakravarti D
and Szyf M: The oncoprotein Set/TAF-1beta, an inhibitor of histone
acetyltransferase, inhibits active demethylation of DNA,
integrating DNA methylation and transcriptional silencing. J Biol
Chem. 277:25026–25031. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li M, Makkinje A and Damuni Z: The myeloid
leukemia-associated protein SET is a potent inhibitor of protein
phosphatase 2A. J Biol Chem. 271:11059–11062. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jun Qi, He P, Chen W, Wang H, Wang X and
Zhang M: Comparative proteome study of apoptosis induced by
As4S4 in retinoid acid resistant human acute
promyelocytic leukemia NB4-R1 cells. Leuk Res. 34:1506–1516. 2010.
View Article : Google Scholar
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
8
|
Lee SG, Park TS, Cho SY, Lim G, Park GJ,
Oh SH, Cho EH, Chong SY and Huh JY: T-cell acute lymphoblastic
leukemia associated with complex karyotype and SET-NUP214
rearrangement: A case study and review of the literature. Ann Clin
Lab Sci. 41:267–272. 2011.PubMed/NCBI
|
|
9
|
Adler HT, Nallaseth FS, Walter G and
Tkachuk DC: HRX leukemic fusion proteins form a heterocomplex with
the leukemia-associated protein SET and protein phosphatase 2A. J
Biol Chem. 272:28407–28414. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neviani P, Santhanam R, Trotta R, Notari
M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al:
The tumor suppressor PP2A is functionally inactivated in blast
crisis CML through the inhibitory activity of the BCR/ABL-regulated
SET protein. Cancer Cell. 8:355–368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ouellet V, Le Page C, Guyot MC, Lussier C,
Tonin PN, Provencher DM and Mes-Masson AM: SET complex in serous
epithelial ovarian cancer. Int J Cancer. 119:2119–2126. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar RN, Radhakrishnan R, Ha JH and
Dhanasekaran N: Proteome analysis of NIH3T3 cells transformed by
activated Galpha12: Regulation of leukemia-associated protein SET.
J Proteome Res. 3:1177–1183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Janssens V and Goris J: Protein
phosphatase 2A: A highly regulated family of serine/threonine
phosphatases implicated in cell growth and signalling. J Biol Chem.
353:417–439. 2001.
|
|
14
|
Westermarck J and Hahn WC: Multiple
pathways regulated by the tumor suppressor PP2A in transformation.
Trends Mol Med. 14:152–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Van Hoof C and Goris J: Phosphatases in
apoptosis: To be or not to be, PP2A is in the heart of the
question. Biochim Biophys Acta. 1640:97–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neviani P, Santhanam R, Oaks JJ, Eiring
AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N,
Gambacorti-Passerini C, et al: FTY720, a new alternative for
treating blast crisis chronic myelogenous leukemia and Philadelphia
chromosome-positive acute lymphocytic leukemia. J Clin Invest.
117:2408–2421. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam
R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, et al:
FTY720 demonstrates promising preclinical activity for chronic
lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood.
111:275–284. 2008. View Article : Google Scholar
|
|
18
|
Arnaud L, Chen S, Liu F, Li B, Khatoon S,
Grundke-Iqbal I and Iqbal K: Mechanism of inhibition of PP2A
activity and abnormal hyperphosphorylation of tau by I2 (PP2A)/SET.
FEBS Lett. 585:2653–2659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lam BD, Anthony EC and Hordijk PL:
Cytoplasmic targeting of the proto-oncogene SET promotes cell
spreading and migration. FEBS Lett. 587:111–119. 2013. View Article : Google Scholar
|
|
20
|
Rong Y and Distelhorst CW: Bcl-2 protein
family members: Versatile regulators of calcium signaling in cell
survival and apoptosis. Annu Rev Physiol. 70:73–91. 2008.
View Article : Google Scholar
|
|
21
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
